UEG Podcast

in this first part, Eglė talks with Dr Pilar Acedo Nuñez, a senior research fellow and junior principal investigator at UCL. Pilar co-leads the Pereira/Acedo Lab, which works on biomarkers for the early detection of pancreatic cancer and cholangiocarcinoma, and she is a former chair of the UEG Young Talent Group.

Further reading

Ten years after Rome IV, the Rome Foundation published Rome V in 2026, and with it a substantial revision of how disorders of gut–brain interaction (DGBI) are defined, diagnosed and managed. Pradeep Mundre is joined by Maura Corsetti, Associate Professor of Gastroenterology at the University of Nottingham, co-chair of the Rome V Bowel Disorders Committee and a member of the Rome Foundation Board of Directors, to work through what has actually changed, and what survives contact with a busy clinic..

Further reading

Asked to choose between a flare and a JAK inhibitor in the third trimester, Mette Julsgaard answers in two words: active disease.

Part two picks up where aspirin for preeclampsia ended and moves to the situations that actually keep clinicians awake. Mette Julsgaard, Associate Professor at Aarhus University Hospital and a co-author of the 2025 global consensus statement on pregnancy in IBD, takes Pradeep Mundre through starting upadacitinib at 28 weeks when nothing else was left, why thiopurines should never be initiated in pregnancy even though they can be continued, and how to manage acute severe ulcerative colitis without letting surgery drift.

Also here: why active perianal disease and a pouch push you towards caesarean section and why BCG waits six months but rotavirus does not.

Part one covers fertility, preconception and the full drug run-through, be sure to listen to it, before you start with this episode.

Further reading:

One in three women with IBD believe every IBD drug is harmful in pregnancy. The cost of that belief shows up as flares, preterm births and babies born small for gestational age.

Mette Julsgaard, Associate Professor at Aarhus University Hospital and Director of Denmark's National Centre for Preconception and Pregnancy in Autoimmune Diseases, was a co-author of the 2025 global consensus statement on pregnancy in IBD. With Pradeep Mundre she works through the period before conception: what active disease does to fertility in men and women, what to check at the preconception visit beyond disease activity, and why the stop list is short (JAK inhibitors, S1P receptor modulators and, in women, methotrexate).

Then a drug by drug run through of pregnancy and breastfeeding, including why the biologics reach breast milk at under 1 % of maternal blood levels, as well as the recommendation for the use of aspirin for patients with IBD during pregnancy.

Part two covers flares, surgery, delivery and vaccination and will be published on the 2nd of September 2026.

Further reading:

The literature said 41 to 46% of high-risk early oesophageal cancers already have nodal disease. Newer data from patients followed after endoscopic resection puts it nearer 16%, which means sending all of them to surgery operates on more than 80% for nothing.

Recorded after the UEG online course on oesophageal cancer, three specialists work through the questions the guidelines have not settled. Roos Pouw on when strict endoscopic follow-up can replace oesophagectomy, and exactly what that follow-up schedule looks like. Ana-Maria Bucalau on why six biopsies no longer covers the biomarker panel, and what ESOPEC and MATTERHORN change about neoadjuvant choice. Jessie Elliott on Siewert type II surgery, and on ENSURE, which found intensive surveillance detects recurrence earlier without improving survival while increasing cancer worry.

The SARONG surveillance trials are still recruiting and Jessie is open to hearing from interested centres. Full course at gutflix.eu.

Further reading:

1. ESGE tissue sampling guideline, Part 1 (biopsy numbers)

UEG Podcast is on summer holiday and re-releases published episodes that we think deserve another listen. Enjoy!

In this episode of the UEG Talks conversation between Maria Vehreschild and Pradeep Mundre, we delve into the complexities of the faecal microbiome and the role of faecal microbiota transplantation (FMT) in treating various diseases, particularly C. difficile infections and inflammatory bowel disease (IBD). The discussion covers the historical context of FMT, its mechanisms of action, current treatment guidelines, safety considerations, and the various delivery methods. The conversation also emphasises the need for further research and the importance of professional standards in FMT practices.

UEG Podcast is on summer holiday and re-releases published episodes that we think deserve another listen. Enjoy!

Functional gastrointestinal disorders, or disorder of gut-brain interaction, can be frightening to many GIs. How do I talk to the patient? What can I tell them if there is no improvement in their symptoms? How can I even explain to them what their diagnosis is, if I don’t even know it?

The content of UEG Talks is for healthcare professionals and is purely educational. The views of the speakers are their own and do not necessarily reflect those of United European Gastroenterology. This podcast is not medical advice and should not replace clinical judgment. Always consult official guidelines and relevant experts before making patient care decisions.

UEG Podcast is on summer holiday and re-releases published episodes that we think deserve another listen. Enjoy!

In this episode, host Egle speaks with former UEG President Axel Dignass about what it takes to lead in times of crisis. Drawing on his experience during the COVID-19 pandemic, Axel reflects on the difference between being a boss and being a true leader. He shares thoughts on the value of empathy, transparency, and consistency, as well as how to build and sustain a resilient team. The conversation also touches on the challenges of going virtual, the importance of recognising team achievements, and the warning signs of toxic leadership. A must-listen for anyone looking to grow as a leader in uncertain times.

The headlines say colorectal cancer is surging in the under-50s. Michael Bretthauer, the colorectal screening authority behind the Nordic trials and the EU-funded ECOPOP consortium, thinks the panic is misplaced, and he has the population data to argue it.

Article on carcinoid tumours, Dr. Montminy

The 2024 EASL guidelines on MASLD are already out of date on treatment, and that's a good problem to have. In part 2, Pradeep Mundre and Professor Sven Francque (Antwerp), guideline co-author, walk through what works now. Lifestyle still earns the hardest numbers: 7% body weight loss for resolution of steatohepatitis, 10% for fibrosis regression. Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, is now approved for F2-F3 fibrosis (though not in every EU country). Semaglutide has produced positive phase 3 data in MASH and an updated guideline is on the way. Sven also covers where pioglitazone, obeticholic acid, and bariatric surgery sit, the particularities of liver transplantation in this older, comorbid population, and an honest answer to what a hepatology trainee should expect from this field. Catch part 1 first if you missed it.

MASLD guidelines